Stem Cell Transplant News

Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome (February 21, 2017)

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation... Continue Reading

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma (October 12, 2016)

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT) (December 14, 2015)

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to... Continue Reading

Complementary Therapy for Children Undergoing Stem Cell Transplant (July 19, 2010)

Complementary therapies such as massage and humor therapy may not help children cope with the potential emotional distress associated with stem cell transplantation, according to findings recently reported in Cancer. Stem cell transplantation involves... Continue Reading

Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)

Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading

Latest Stem Cell Transplant News By Stage


Allogeneic Stem Cell Transplant

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Complementary Therapy for Children Undergoing Stem Cell Transplant (July 19, 2010)

Complementary therapies such as massage and humor therapy may not help children cope with the potential emotional distress associated with stem cell transplantation, according to findings recently reported in Cancer. Stem cell transplantation involves... Continue Reading

More Allogeneic Stem Cell Transplant

Autologous Stem Cell Transplant

Complementary Therapy for Children Undergoing Stem Cell Transplant (July 19, 2010)

Complementary therapies such as massage and humor therapy may not help children cope with the potential emotional distress associated with stem cell transplantation, according to findings recently reported in Cancer. Stem cell transplantation involves... Continue Reading

Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)

Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading

More Autologous Stem Cell Transplant